191 related articles for article (PubMed ID: 29754945)
1. Decision analysis defining optimal management of clinical stage 1 high-risk nonseminomatous germ cell testicular cancer with lymphovascular invasion.
Avulova S; Allen C; Morgans A; Moses KA
Urol Oncol; 2018 Jul; 36(7):342.e1-342.e6. PubMed ID: 29754945
[TBL] [Abstract][Full Text] [Related]
2. Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours.
Flechtner HH; Fischer F; Albers P; Hartmann M; Siener R;
Eur Urol; 2016 Mar; 69(3):518-25. PubMed ID: 26620368
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
[TBL] [Abstract][Full Text] [Related]
4. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
6. Management of patients with low-stage nonseminomatous germ cell testicular cancer.
Stephenson AJ; Sheinfeld J
Curr Treat Options Oncol; 2005 Sep; 6(5):367-77. PubMed ID: 16107240
[TBL] [Abstract][Full Text] [Related]
7. Current management of stage I testicular germ cell tumors in a French cancer institute. A practice analysis over the 10 past years.
Chanal E; Bouleftour W; Guillot A; Rowinski E; Bernichon E; Tremeau L; Lardon R; Lacroix B; Lorin S; Delorme G; Perraud Y; Armand C; Levigne F; Vallard A; Langrand-Escure J; Fournel P; Benoite M; Vassal C
Bull Cancer; 2019 Dec; 106(12):1086-1093. PubMed ID: 31582176
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.
Vidal AD; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
Ann Oncol; 2015 Feb; 26(2):374-7. PubMed ID: 25392157
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study.
Tandstad T; Cohn-Cedermark G; Dahl O; Stierner U; Cavallin-Stahl E; Bremnes RM; Klepp O
Ann Oncol; 2010 Sep; 21(9):1858-1863. PubMed ID: 20142410
[TBL] [Abstract][Full Text] [Related]
10. The value of prognostic factors in the management of stage I nonseminomatous germ cell testicular tumors (NSGCTT).
Ondrus D; Goncalves F; Kausitz J; Mat'oska J; Belan V
Neoplasma; 1996; 43(3):195-7. PubMed ID: 8841507
[TBL] [Abstract][Full Text] [Related]
11. Management of stage I testicular germ cell tumours.
Chovanec M; Hanna N; Cary KC; Einhorn L; Albany C
Nat Rev Urol; 2016 Nov; 13(11):663-673. PubMed ID: 27618772
[TBL] [Abstract][Full Text] [Related]
12. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
[TBL] [Abstract][Full Text] [Related]
13. Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer.
Heidenreich A; Paffenholz P; Nestler T; Pfister D
Oncol Res Treat; 2018; 41(6):370-378. PubMed ID: 29772568
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Risk-adapted Surveillance vs Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: A Retrospective Follow-up Study of 81 Patients.
Fan G; Zhang L; Yi L; Jiang ZQ; Ke Y; Wang XS; Xiong YY; Han WQ; Zhou X; Liu C; Yu X
Asian Pac J Cancer Prev; 2015; 16(8):3267-72. PubMed ID: 25921130
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen.
Dowling CM; Assel M; Musser JE; Meeks JJ; Sjoberg DD; Bosl G; Motzer R; Bajorin D; Feldman D; Carver BS; Sheinfeld J
Urology; 2018 Apr; 114():133-138. PubMed ID: 29410311
[TBL] [Abstract][Full Text] [Related]
16. Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysis.
Nguyen CT; Fu AZ; Gilligan TD; Wells BJ; Klein EA; Kattan MW; Stephenson AJ
J Clin Oncol; 2010 Jan; 28(1):119-25. PubMed ID: 19917846
[TBL] [Abstract][Full Text] [Related]
17. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
[TBL] [Abstract][Full Text] [Related]
18. Early clinical stages of nonseminomatous testis cancer. Evaluation of the primary treatment and follow-up procedures of the SWENOTECA project.
Klepp O; Olsson AM; Ous S; Nilsson S; Høisaether PA; Tveter K
Scand J Urol Nephrol; 1991; 25(3):179-90. PubMed ID: 1658924
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors.
Gumus M; Bilici A; Odabas H; Ustaalioglu BBO; Kandemir N; Demirci U; Cihan S; Bayoglu IV; Ozturk T; Turkmen E; Urakci Z; Seker MM; Gunaydin Y; Selcukbiricik F; Turan N; Sevinc A
World J Urol; 2017 Jul; 35(7):1103-1110. PubMed ID: 27812752
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Survival of Good-Risk Germ Cell Tumor Patients After Postchemotherapy Retroperitoneal Lymph Node Dissection: A Comparison of BEP × 3 vs. EP × 4 and Treating Institution.
Cary C; Jacob JM; Albany C; Masterson TA; Hanna NH; Einhorn LH; Foster RS
Clin Genitourin Cancer; 2018 Apr; 16(2):e307-e313. PubMed ID: 29104087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
